MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Coherus BioSciences Accounts Receivables 2011-2026 | CHRS
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Coherus BioSciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 261 M | 110 M | 123 M | 157 M | 142 M | - | - | 1.86 M | 1.56 M | 2.42 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 261 M | 1.56 M | 99.8 M |
Quarterly Accounts Receivables Coherus BioSciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.24 M | 5.11 M | 60.5 M | 111 M | 168 M | 175 M | 252 M | 261 M | 217 M | 141 M | 101 M | 110 M | 91.2 M | - | 117 M | 123 M | 136 M | 142 M | 140 M | 157 M | 157 M | 157 M | 157 M | 142 M | 142 M | 142 M | 142 M | - | - | - | - | - | - | - | 26 K | 1.86 M | 1.86 M | 1.86 M | 1.86 M | 1.56 M | 1.56 M | 1.56 M | 1.56 M | 2.42 M | 2.42 M | 2.42 M | 2.42 M | 278 K | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 261 M | 26 K | 89.5 M |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AgeX Therapeutics
AGE
|
57 K | - | -10.17 % | $ 12.2 K |  USA |
 |
Adagene
ADAG
|
3 M | $ 1.65 | 7.91 % | $ 92.9 M |  China |
 |
Arrowhead Pharmaceuticals
ARWR
|
6.82 M | $ 66.05 | 2.3 % | $ 8.83 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
109 K | $ 1.52 | -16.3 % | $ 388 M |  Britain |
 |
Biogen
BIIB
|
1.4 B | $ 184.48 | -1.67 % | $ 26.9 B | USA |
 |
BeiGene, Ltd.
BGNE
|
676 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
205 K | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
18.5 M | - | -7.31 % | $ 87 M | USA |
 |
Bristol-Myers Squibb Company
BMY
|
10.7 B | $ 55.71 | -0.28 % | $ 113 B | USA |
 |
Acasti Pharma
ACST
|
802 K | - | 4.01 % | $ 150 M |  Canada |
 |
Zai Lab Limited
ZLAB
|
85.2 M | $ 18.37 | -0.97 % | $ 18.2 B | China |
 |
Catalyst Biosciences
CBIO
|
1.82 M | $ 10.84 | 0.46 % | $ 714 M | USA |
 |
Caladrius Biosciences
CLBS
|
900 K | - | -16.75 % | $ 25.8 M | USA |
 |
Celldex Therapeutics
CLDX
|
700 K | $ 25.59 | -6.54 % | $ 1.65 M | USA |
 |
Clearside Biomedical
CLSD
|
170 K | - | - | $ 25.3 M | USA |
 |
Chimerix
CMRX
|
4 K | - | - | $ 756 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
821 K | - | -15.15 % | $ 60.3 M | Britain |
 |
Corcept Therapeutics Incorporated
CORT
|
54 M | $ 37.35 | -0.4 % | $ 3.86 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
65.5 M | $ 23.18 | 2.02 % | $ 2.75 B | USA |
 |
AIkido Pharma
AIKI
|
200 K | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
3.27 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
392 K | - | - | $ 2.17 B | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
8.3 M | $ 55.11 | 3.49 % | $ 4.45 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
25 M | $ 55.17 | 2.47 % | $ 4.65 B |  Schweiz |
 |
Ayala Pharmaceuticals
AYLA
|
234 K | - | - | $ 7.46 M |  Israel |
 |
Zentalis Pharmaceuticals
ZNTL
|
3.34 M | $ 3.53 | -5.75 % | $ 231 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
136 M | $ 29.43 | 6.09 % | $ 1.43 B | USA |